Croda International Plc (LSE:CRDA) agreed to acquire Solus Biotech Co., Ltd. from Solus Advanced Materials Co., Ltd. (KOSE:A336370) for KRW 350 billion on February 3, 2023. The acquisition is subject to regulatory approval. Lazard & Co., Limited acted as financial advisor to Croda International Plc (LSE:CRDA).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18,050 KRW | -1.20% |
|
+1.06% | +36.23% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.23% | 981M | |
+13.68% | 108B | |
-3.39% | 30B | |
+6.15% | 21.06B | |
-12.82% | 18.45B | |
-11.52% | 16.3B | |
+10.71% | 15.47B | |
+7.49% | 12.84B | |
0.00% | 11.02B | |
+14.37% | 8.37B |
- Stock Market
- Equities
- A336370 Stock
- News Solus Advanced Materials Co., Ltd.
- Croda International Plc agreed to acquire Solus Biotech Co., Ltd. from Solus Advanced Materials Co., Ltd. for KRW350 billion.